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Case report 
A 48-year-old male presented to the Emergency De-
partment in the middle of  the night with lower-back pain 
and dysuria. The patient had recently been treated with 
oral ciprofloxacin as an outpatient for a presumed urinary-
tract infection. The patient’s past medical history was sig-
nificant only for hypertension, managed with clonidine. A 
urine analysis before imaging workup revealed positive 
urine nitrates, leukocytosis, and white blood cells, consistent 
with history of  recent urinary-tract infection.
A contrast-enhanced CT of  the abdomen and pelvis was 
then ordered to assess for causes of  the patient’s flank pain 
and to rule out an ascending genitourinary infection. The 
CT demonstrated a large 6.8cm left adrenal mass with pre-
dominantly peripheral enhancement and central areas of  
low attenuation, presumed to represent necrosis (Fig. 1). No 
imaging findings of  cystitis or pyelonephritis were 
demonstrated. 
The diagnostic considerations for the adrenal mass were 
broad and included primary adrenal carcinoma, metastasis,  
neuroendocrine etiologies, and (less likely) adrenal hemor-
rhage. The patient was subsequently admitted to the hospi-
tal; on the following day, he underwent an MRI of  the 
adrenals performed without the use of  intravenous contrast 
material. The lesion did not demonstrate any signal loss on 
out-of-phase imaging, as would be expected with lipid-rich 
lesions such as adenomas (Fig. 2). On the T2-weighted se-
quence, the lesion was heterogeneous but showed large 
regions of  hyperintensity (Fig. 3). 
At this time, the patient was discharged and followed by 
the endocrinology service. On further review of  systems, 
the patient indicated that he had been having intermittent 
palpitations, diaphoresis, and headaches. Laboratory 
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Figure 1. 48-year-old male with pheochromocytoma. Axial, 
contrast-enhanced CT demonstrated a 6.8cm left adrenal 
mass (arrow) with predominantly peripheral enhancement 
and central necrosis (arrow). The lesion implied mass effect 
and posterior displacement of the left kidney.
evaluation revealed an elevated 24-hour level of  urinary 
total metanephrines, measuring 14,168 mcg (normal range: 
less than 739 mcg/24 hours). At this point, a presumptive 
diagnosis of  pheochromocytoma was made, and the patient 
underwent an I-123 MIBG nuclear-medicine scan to fur-
ther evaluate the extent of  disease and to confirm the diag-
nosis. The study demonstrated that the left adrenal mass 
was strongly MIBG-avid (Fig. 4), supporting the clinical 
diagnosis of  pheochromocytoma. No focal MIBG uptake 
was identified elsewhere to suggest metastasis.
The patient was subsequently placed on the alpha-
blocking antihypertensive phenoxybenzamine and under-
went laparoscopic left adrenalectomy. Gross pathology (Fig. 
5a) revealed an encapsulated rubbery, red-brown mass aris-
ing from the adrenal medulla with histologic findings (Fig. 
5b) supporting the diagnosis of  pheochromocytoma.
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Figure 2.48-year-old male with pheochromocytoma. Axial (A) and coronal (C) in-phase MR images showed the heterogeneous 
left adrenal mass (arrows). During the axial (B) and coronal (D) out-of-phase images, there was no loss of signal in the mass 
(arrows).
Figure 3. 48-year-old male with pheochromocytoma. Axial, 
T2-weighted MR showed a central area of hyperintensity 
(arrow) within the left adrenal mass.
Figure 4. 48-year-old male with pheochromocytoma. Four 
hours following I-123 MIBG administration, anterior and 
posterior whole-body planar images (A) and fused SPECT-
CT images (B) revealed focal concentrated uptake of MIBG 
(arrows) within the left adrenal gland consistent with a 
pheochromocytoma. No other areas of focal MIBG activity 
were seen to suggest metastasis. Physiologic uptake was 
identified within the salivary glands, liver, and urinary blad-
der on the planar images.
Discussion
Pheochromocytomas are uncommon neuroendocrine 
tumors arising from chromaffin cells of  the adrenal medulla 
(2, 3, 4). In approximately 10% of  cases, these tumors can 
arise from extra-adrenal paraganglionic chromaffin tissues 
and are referred to as paragangliomas (2, 5). The result of  
unregulated catecholamine secretion from these tumors can 
result in a classic clinical symptomatology of  episodic hy-
pertension, headaches, and palpitation; however, if  left un-
treated, pheochromocytomas can lead to malignant hyper-
tensive crises, cardiac arrhythmias, and death (2, 6, 7). Due 
to the risks of  biopsy or manipulation of  a pheochromocy-
toma, an accurate diagnosis and subsequent pre-operative 
alpha-blockade are essential in the workup of  this condition 
(2, 3, 5, 7).
Classically, pheochromocytomas have been said to follow 
a “rule of  10s”: 10% are bilateral, 10% are extra-adrenal, 
10% are silent, and 10% of  intra-adrenal pheochromocy-
tomas are malignant (2, 6, 8, 9). Up to 25% of  pheochro-
mocytomas have an associated genetic predisposition, with 
a smaller percentage related to broader syndromic states 
such as multiple endocrine neoplasias (MEN) II and III, 
Sturge-Weber, neurofibromatosis, and von Hippel-Lindau 
(2, 5, 8). 
The role of  imaging in characterizing these lesions is 
important but complementary to the clinical presentation. 
In addition to the aforementioned clnical symptoms, first-
line laboratory diagnostic evaluation entails measurement 
of  plasma metanephrines and 24-hour urinary catechola-
mine and vanillymandelic acid levels (2, 7, 8, 9).
Pheochromocytomas larger than 3cm often have a vari-
able appearance on CT and can mimic many other adre-
nal lesions (2, 8). While they are typically well-defined, with 
attenuation greater than 10 hounsfield-units, larger lesions 
can develop a more heterogeneous appearance due to in-
ternal necrosis and hemorrhage (Fig. 6a) (2, 5). Due to a 
rich capillary network, pheochromocytomas demonstrate 
avid enhancement with variable washout dynamics on de-
layed images (2). While there are theoretical concerns re-
garding the use of  iodinated intravenous contrast agents, 
several sources report the safety of  using nonionic low-
molecular-weight agents if  necessary (3, 4, 6, 7, 8).
Although signal intensity is variable on MR imaging, 
pheochromocytomas have classically been described to 
have a “light-bulb” hyperintensity on T2-weighted se-
quences, due to a cystic component, and are hypointense 
on T1 sequences (2, 5, 9). However, the presence of  T2 
hyperintensity is neither sensitive or specific for pheochro-
mocytoma, and considerable variability exists in the uni-
formity and distribution of  T2-signal involving these le-
sions (Fig. 6b) (2, 10). A retrospective study of  44 cases of  
pheochromocytoma found only 11% demonstrating the 
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Figure 5. 48-year-old male with pheochromocytoma. Gross 
pathology (A) revealed an encapsulated red-brown pheo-
chromocytoma, measuring 7cm and 139g. Hematoxylin and 
eosin stain (B) revealed pleomorphic nuclei with character-
istic nests of cells ("zellballen") and abundant cytoplasm 
(1).
Figure 6A. 48-year-old male with pheochromocytoma. Co-
ronal post-contrast CT demonstrated a heterogeneously 
enhancing left adrenal pheochromocytoma with central 
necrosis.
classic homogeneous, T2-hyperintense appearance; 34% 
were described as homogeneously hypointense to CSF T2 
signal, 16% showed a heterogeneous “marbled” appear-
ance, and 39% were heterogeneous with cystic pockets of  
T2 hyperintensity (10). Due to the rich vascular network 
within these tumors, punctate flow-voids are described as 
having a “salt-and-pepper” appearance (2). While signal 
loss on out-of-phase imaging is more commonly associated 
with a lipid-rich adenoma, a pheochromocytoma can also 
occasionally show signal loss due to intracellular fat content 
(2). 
Radionuclide scintigraphy, particularly when coupled 
with SPECT/CT, plays an important role in localizing 
extra-adrenal disease, assessing for distant metastases, and 
evaluating for tumor recurrence (2, 5, 11, 12). The most 
specific radiotracer used is metaiodobenzylguanidine 
(MIBG), labeled with radioiodine 123 or 131, whose speci-
ficity for detecting pheochromocytomas approaches 100% 
(Fig. 6c) (2, 9). MIBG acts as a norepinephrine analog and 
is stored in neurosecretory granules of  chromaffin cells (9). 
Although less specific, In-111 octreotide, a somatostatin-
analog, is a second agent that can be used to localize pheo-
chromocytomas; it may serve a complementary role, par-
ticularly in evaluating nonfunctioning paragangliomas and 
dopamine-secreting metastases (2, 9, 12). The use of  PET 
and PET/CT is also coming into practice, with new F-18-
labeled tracers (DOPA, FDA) providing better sensitivity 
and specificity than the commonly used FDG (2, 9, 11, 12). 
However, due to continued investigation of  these agents, 
cost, and limited availablity of  these analogs, the use of  
PET is not yet widespread (2, 12).
As illustrated in this case, the use of  multi-modality im-
aging provides an important role in guiding the diagnosis 
and directing pre-operative planning for pheochromocy-
tomas.
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